扁平苔藓患者整体及部位特异性癌症风险
这项基于丹麦全国登记数据的回顾性队列研究纳入35 845例新发扁平苔藓(LP)患者,比较其与一般人群的癌症发生率。结果显示,女性任何LP患者口腔癌(舌SIR=6.8,95%CI 5.4-8.4)和外阴癌(SIR=2.6,95%CI 2.0-3.4)风险显著升高,鳞状细胞癌风险轻度升高(SIR=1.4,95%CI 1.3-1.6),肺癌风险降低(SIR=0.7,95%CI 0.6-0.8);男性模式相似。部位特异性分析显示口腔LP患者口腔癌风险最高,生殖器LP患者生殖器癌风险最高。20年绝对风险较低,但部位特异性癌症应视为LP可能的长期并发症。
要点
- 任何LP患者口腔癌风险显著升高,舌癌SIR=6.8(95%CI 5.4-8.4)。
- 女性LP患者外阴癌风险升高(SIR=2.6,95%CI 2.0-3.4),男性模式相似。
- 口腔LP和生殖器LP分别与对应部位癌症风险最高相关。
核心结论
- LP与口腔癌和生殖器癌风险显著升高相关,皮肤癌风险轻度升高,且风险升高部位与LP解剖位置对应。
- 尽管绝对风险较低,部位特异性癌症应视为LP可能的长期并发症。
研究设计与样本
- 回顾性队列研究,使用丹麦全国登记数据(1978-2020年)纳入35 845例新发LP患者(女性21 650例,男性14 195例),无既往癌症。
- 通过国家患者登记册(任何LP)和丹麦病理登记册(任何LP及部位特异性LP)识别LP诊断。
主要发现
- 女性任何LP患者口腔癌风险升高:唇SIR=6.0(95%CI 3.3-10.0)、口腔腔SIR=7.5(95%CI 6.4-8.9)、舌SIR=6.8(95%CI 5.4-8.4)。
- 女性任何LP患者外阴癌SIR=2.6(95%CI 2.0-3.4),鳞状细胞癌SIR=1.4(95%CI 1.3-1.6),肺癌SIR=0.7(95%CI 0.6-0.8)。
- 男性LP患者癌症风险模式与女性相似。
- 部位特异性分析显示口腔LP患者口腔癌风险最高,生殖器LP患者生殖器癌风险最高。
- 20年绝对风险:女性/男性口腔腔癌0.8%(95%CI 0.7%-1.0%)/1.0%(95%CI 0.8-1.2),舌癌0.5%(95%CI 0.4%-0.6%)/0.6%(95%CI 0.5%-0.8%),唇癌0.1%(95%CI 0%-0.1%)/0.2%(95%CI 0.1%-0.3%),生殖器癌0.4%(95%CI 0.2%-0.5%)/0.2%(95%CI 0.1%-0.2%)。
临床怎么用
- 对LP患者,尤其是口腔LP和生殖器LP患者,应关注对应部位癌症的长期监测。
- 尽管绝对风险低,临床随访中需考虑部位特异性癌症作为LP的长期并发症。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The association between lichen planus (LP) and subsequent cancer risk, particularly by anatomical site, is not well established. OBJECTIVE: To assess the association between any LP, and site-specific LP, and the subsequent risk of cancer compared to the general population. DESIGN, SETTINGS, AND PARTICIPANTS: This was a retrospective cohort study using nationwide Danish register-based data of individuals with an incident LP diagnosis (1978-2020), with no prior cancer, identified through the National Patient Register (any LP) and the Danish Pathology Register (any LP and site-specific LP). Data were analyzed from August 20 to December 20, 2025. EXPOSURES: Any diagnosis of LP independent of site, and LP at specific anatomical sites (oral, cutaneous, and genital). MAIN OUTCOMES AND MEASURES: Participants were followed up for incident cancer outcomes until death, emigration, or December 31, 2023. Cancers were identified through the Danish Cancer Register. Standardized incidence ratios (SIRs) with 95% CIs were calculated separately for females and males, comparing cancer incidence in patients with LP to the general Danish female or male population. RESULTS: A total of 35 845 patients with LP (21 650 females and 14 195 males) were included in the analysis. Compared to the general population, females with any LP had increased risk of oral cancers (lip, SIR = 6.0; 95% CI, 3.3-10.0; oral cavity, SIR = 7.5; 95% CI, 6.4-8.9; tongue, SIR = 6.8; 95% CI, 5.4-8.4) and vulvar cancer (SIR = 2.6; 95% CI, 2.0-3.4), while the risk of squamous cell carcinoma was slightly elevated (SIR = 1.4; 95% CI, 1.3-1.6). In contrast, lung cancer risk was decreased (SIR = 0.7; 95% CI, 0.6-0.8). Results were consistent across follow-up. The cancer risk pattern was similar in male patients with LP. Site-specific analyses showed the highest risk of oral cancers in patients with oral LP, and of genital cancer in patients with genital LP. The 20-year absolute risks in female and male patients were 0.8% (95% CI, 0.7%-1.0%) and 1.0% (95% CI, 0.8-1.2) for oral cavity cancers, 0.5% (95% CI, 0.4%-0.6%) and 0.6% (95% CI, 0.5%-0.8%) for tongue cancers, 0.1% (95% CI, 0%-0.1%) and 0.2% (95% CI, 0.1%-0.3%) for lip cancers, and 0.4% (95% CI, 0.2%-0.5%) and 0.2% (95% CI, 0.1%-0.2%) for genital cancers, respectively. CONCLUSIONS AND RELEVANCE: In this cohort study, LP was associated with markedly increased risks of oral and genital cancers, as well as a slightly increased risk of skin cancer, particularly at sites corresponding to the anatomical LP location. While the absolute risk is low, site-specific cancer should be considered a possible long-term complication of LP.
引用
- Medianfar CE, Kaderly Rasmussen EL, Baandrup L, et al. Cancer Risk in Patients With Overall and Site-Specific Lichen Planus. JAMA Dermatol. 2026. PMID: 42873519. doi:10.1001/jamadermatol.2026.3933
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。